Neoantigen Vaccine Market

Report Code - HC2022918HJ | Industry - Healthcare | Published on - September, 2022 | Pages - 107 | Format -

Neoantigen Vaccine Market by Product Type, Application and Region - Global Market Analysis and Forecast (2019 - 2029)




The global neoantigen vaccine market outlook study is a comprehensive databook that provides key market data on the global neoantigen vaccine industry. Some of the prominent players in the market are Advaxis, Agenus Inc, Avidea Technologies, BioNTech, BrightPath Biotherapeutics, Eli Lilly and Company, Genocea Biosciences Inc, Gritstone Bio, ISA Pharmaceuticals, Medigene AG, Merck & Co Inc, Moderna, Nouscom, Novogene, OSE Immunotherapeutics, Pfizer, Roche Holding AG, Vaccibody AS, Vaximm AG, ZIOPHARM Oncology. The research report on the global neoantigen vaccine market provides extensive competition analysis and competitive conditions. The report includes information on significant products, players, challenges and developments, and other information specific to the market.

Goals and Objectives of the Global Neoantigen Vaccine Market Study

The purpose of this study is to identify the current market environment for neoantigen vaccine and to assess the market's potential for growth over the forecast period. The research delves into market factors affecting the neoantigen vaccine market (drivers, restraints, opportunities, and trends). The current market for neoantigen vaccine is examined in this report, as well as the market's future trajectory.

  • The reasons for doing this study are to:
    • To generate a detailed industry structure, provide a comprehensive analysis of the neoantigen vaccine market industry and its segments in the global market.
    • Provide detailed insights into the factors driving and restraining the global market for neoantigen vaccine growth.
    • Estimate the size of the global market for neoantigen vaccine.
    • Examine the global market for neoantigen vaccine in terms of key countries and regions.
    • Provide country-level market value analysis for key segments of the neoantigen vaccine market.
    • Provide strategic profiling of key global companies, as well as a thorough analysis of their competitiveness and the overall competitive landscape in this market.

The second chapter, market overview, provides an overview of the neoantigen vaccine market. The chapter discusses macroeconomic factors, drivers, restraints, opportunities, challenges, value chain analysis, technology roadmap, and Porter 5 force model analysis.

Scope of the Report

The global neoantigen vaccine market is extensive, with a detailed description and evaluation of the market. It includes extensive qualitative and quantitative insights into the report that are aligned with our intended customers' goals and objectives.

Attribute Description
Base Year 2022
Historical Year 2019 - 2021
Forecast Period 2023 - 2029
Market Value US$ Million
Segments Covered

By Product Type: Personalized Vaccine, Off-the shelf Vaccine.

By Application: Lung Cancer, Melanoma Cancer, Gastrointestinal Cancer, Brain Cancer, Others.

Geographies Covered

North America: U.S., Canada

Europe: Germany, U.K., France, Italy, Spain, Russia, and the Rest of Europe

Asia Pacific: China, India, Japan, Australia, and the Rest of Asia Pacific

The Middle East and Africa: GCC, South Africa, and the Rest of Middle East and Africa

Latin America: Brazil, Mexico, and the Rest of Latin America

Companies Advaxis, Agenus Inc, Avidea Technologies, BioNTech, BrightPath Biotherapeutics, Eli Lilly and Company, Genocea Biosciences Inc, Gritstone Bio, ISA Pharmaceuticals, Medigene AG, Merck & Co Inc, Moderna, Nouscom, Novogene, OSE Immunotherapeutics, Pfizer, Roche Holding AG, Vaccibody AS, Vaximm AG, ZIOPHARM Oncology

Covid-19 Impact Analysis

The global economy is highly affected by COVID-19. Various sectors in the economy are much affected by this pandemic. The global economy will decline because of the loss of trillions of dollars. The growing extension and imposition of lockdown in various countries directly affect the economy all over the world. The report consists of a chapter that provides a detailed study of the impact of COVID-19 on the neoantigen vaccine market. This report is helpful for business and industry practitioners. The study specifically intended to assist in explaining, directing, and understanding the potential of the neoantigen vaccine markets. The study focuses on providing readers with an understanding of developments in the industry. The report also provides detailed insights on market segments, market forecasts, leading players, market drivers, and inhibitors.

Global Neoantigen Vaccine Market Segmentation

Chapter 3, segment analysis provides information on the different sub-segments of the market. The chapter provides an in-depth analysis of the market segments and year-on-year growth projections that enable readers to identify potential market growth areas.

  • Based on product type, the global neoantigen vaccine market is segmented into personalized vaccine, off-the shelf vaccine.
  • Based on application, the neoantigen vaccine market is segmented into lung cancer, melanoma cancer, gastrointestinal cancer, brain cancer, others.

Global Neoantigen Vaccine Market Regional Analysis

Chapter 4, the regional analysis includes an in-depth analysis of the neoantigen vaccine market by region. The chapter covers several regions, including North America, Europe, Asia-Pacific, the Middle East and Africa, and Latin America. The report also includes a comprehensive analysis of the market by country. The report covers countries such as the United States, Canada, Germany, France, Italy, Spain, China, India, Japan, the GCC, South Africa, Brazil, Mexico, and the rest of the world. Regional insight helps market competitors to make crucial decisions about their company. Individualized, country-wise, and segment-wise analyses by region allow readers to explore the potential of the market in different geographies. This section is a vital part of the report for each year’s growth projections and a global share of value.

Global Neoantigen Vaccine Market Competitive Analysis

Chapter 5, a competitive analysis of the report includes company shares analysis, a list of acquisitions, mergers, collaboration, and the introduction of new products.

Global Neoantigen Vaccine Market Company Profile

Chapter 6, the company profile of the report also covers key industry players working in the neoantigen vaccine market. The report also discusses the business strategies adopted by the players at the global, regional, and country-level. The study also focuses on various businesses or inorganic business development strategies for expanding consumer networks through product formation, organization extension, partnerships, mergers, and acquisitions.

Sources of Information

  • Primary Research: Email correspondence and phone interviews are two common methods of conducting primary research. Primary interviews aid in the validation of data and information, the development of secondary sources, and the collection of data for market nodes where secondary sources are unavailable. Participants in this type of process typically include:
    • CEOs, VPs, marketing/product managers, market intelligence managers, and national sales managers are among the industry participants.
    • External experts include investment bankers, valuation specialists, and research analysts who specialize in specific medical equipment markets.
  • Secondary Research: The research process entails conducting extensive secondary research on internal and external sources to gather qualitative and quantitative market information. The first step in the secondary research is to prepare a list of companies and product mapping for market nodes. The next step is to collect data and information from the public domain for the market nodes. The following are examples of secondary research sources:
    • Financial reports, broker reports, investor presentations, and SEC filings.
    • Journals of industry, scientific journals, and other technical literature
    • Patent and regulatory databases that are relevant.
    • Documents from the national government and statistical databases
    • News articles, press releases, and webcasts specific to market participants.

1. Introduction

2. Market Overview

2.1. Global Neoantigen Vaccine Market Introduction

2.2. Macro- Economic Factor

2.3. Market Determinants

2.3.1. Market Driver

2.3.2. Market Restraints

2.3.3. Market Opportunities

2.3.4. Market Challenges

2.4. Technology/Product Roadmap

2.5. PEST Analysis

2.6. Market Growth Opportunity Analysis

2.7. Impact of Covid-19 on Neoantigen Vaccine Market

3. Market Segmentation

3.1. Global Neoantigen Vaccine Market Analysis (US$ Mn), By Product Type, 2019 - 2029

3.1.1 Personalized Vaccine

3.1.2 Off-the shelf Vaccine

3.2. Global Neoantigen Vaccine Market Analysis (US$ Mn), By Application, 2019 - 2029

3.2.1 Lung Cancer

3.2.2 Melanoma Cancer

3.2.3 Gastrointestinal Cancer

3.2.4 Brain Cancer

3.2.5 Others

4. Regional Analysis

4.1. North America Neoantigen Vaccine Market Analysis (US$ Mn), 2019 - 2029

4.1.1. By Country

4.1.1.1. U.S.

4.1.1.2.Canada

4.1.2.By Product Type

4.1.3.By Application

4.2.Europe Neoantigen Vaccine Market Analysis (US$ Mn), 2019 - 2029

4.2.1.By Country

4.2.1.1.Germany

4.2.1.2.U.K.

4.2.1.3.France

4.2.1.4.Italy 

4.2.1.5.Spain

4.2.1.6.Rest of Europe

4.2.2.By Product Type

4.2.3.By Application

4.3.Asia Pacific Neoantigen Vaccine Market Analysis (US$ Mn), 2019 - 2029

4.3.1.By Country

4.3.1.1.China

4.3.1.2.Japan

4.3.1.3.India

4.3.1.4.Rest of Asia Pacific

4.3.2.By Product Type

4.3.3.By Application

4.4.Rest of world Neoantigen Vaccine Market Analysis (US$ Mn), 2019 - 2029

4.4.1. By Region

4.4.1.1. Middle East & Africa

4.4.1.2. Latin America

4.4.2.By Product Type

4.4.3. By Application

5.Company Profiles 

5.1 Advaxis

5.2 Agenus Inc

5.3 Avidea Technologies

5.4 BioNTech

5.5 BrightPath Biotherapeutics

5.6 Eli Lilly and Company

5.7 Genocea Biosciences Inc

5.8 Gritstone Bio

5.9 ISA Pharmaceuticals

5.10 Medigene AG

5.11 Merck & Co Inc

5.12 Moderna

5.13 Nouscom

5.14 Novogene

5.15 OSE Immunotherapeutics

5.16 Pfizer

5.17 Roche Holding AG

5.18 Vaccibody AS

5.19 Vaximm AG

5.20 ZIOPHARM Oncology

 

Request for Sample Report


Full Name
Company
Job Title/Designation
Business Email
Address
Country
Contact Number
Description
I acknowledge that I have read the Privacy Policy

Inquiry Before Buying


Full Name
Company
Job Title/Designation
Business Email
Address
Country
Contact Number
Description
I acknowledge that I have read the Privacy Policy

Speak to Analyst


Full Name
Company
Job Title/Designation
Business Email
Address
Country
Contact Number
Description
I acknowledge that I have read the Privacy Policy